NeoGenomics Announces Move to NASDAQ Capital Market

NeoGenomics

, a leading provider of cancer-focused genetic testing services, announced today that its common stock has been approved for listing on the NASDAQ Capital Market. The company expects to commence trading on the NASDAQ Capital Market on Monday, December 10, 2012 under the ticker symbol "NEO".  Prior to the listing change to NASDAQ, the company's common stock will continue to trade on the OTC Bulletin Board under the current ticker symbol "NGNM". Douglas VanOort, the company's Chairman and CEO, commented, "The transition to the NASDAQ Capital Market is a significant milestone for NeoGenomics and reflects the strong revenue and operating income growth we have achieved over the last several years.  We believe this move will increase the visibility and liquidity of our shares in the market, and we are honored to join the long list of prestigious companies already traded on NASDAQ."     In honor of the transition to NASDAQ, Douglas VanOort, Chairman and CEO, and other NeoGenomics colleagues will ring the closing bell at The NASDAQ Stock Market in Times Square in New York on Thursday, December 13th. About NeoGenomics, Inc. NeoGenomics, Inc. is a high-complexity CLIA–certified clinical laboratory that specializes in cancer genetics testing, the